Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Business Wire•07/10/2026•08:31 ET
0
Key Highlights
- ➤Taiwan FDA approved Part 2 HARMONIC protocol for LP-300 in September 2026
- ➤Taiwan lead site received IRB approval and opened patient screening September 29
- ➤Part 2 targets EGFR exon 21 L858R patients, extending LP-300 dosing to eight cycles
- ➤L858R patients completing six cycles showed 8.9-month median progression-free survival
- ➤Lantern is exploring regional licensing, partnering and co-development opportunities for LP-300
Expert Statements
Panna Sharma, President and Chief Executive Officer, Lantern Pharma Inc.
“Never-smoker lung cancer is most common in East Asia. In Taiwan, more than half of lung cancer occurs in never-smokers, and a meaningful share of those patients carry the L858R mutation, where outcomes on current targeted therapies have lagged those of other EGFR-mutant patients. What we see in Taiwan is what clinicians see across the region. With these approvals, the next stage of HARMONIC™ opens where the need is high and where we expect enrollment to be efficient. That matters for how quickly we can get to a clear answer on LP-300.”
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
* The Taiwan FDA approved the amended protocol and the lead Taiwan site received IRB approval during September of 2026.
Get started
Create a free account to read the full story.